Anti Infective Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Anti Infective Drugs Market Analysis
The anti-infective drugs market is expected to witness a CAGR of 3.5% over the forecast period.
During the COVID-19 pandemic, several communities, industries, businesses, and lives were adversely affected owing to the restrictions imposed by various countries. In the initial phase of the pandemic, almost all sectors were affected by the COVID-19 pandemic. However, the use of anti-infective drugs came into focus to prevent the spread of the SARS-CoV-2 virus, along with other infectious agents that worsened the condition of the affected population. For instance, in an article published in the International Journal of Clinical Practices in April 2021, several anti-infective drugs effectively treat the SARS-CoV-2 virus. Nitazoxanide, doxycycline, and azithromycin were highly effective for the symptomatic improvement of mild and moderate COVID19 patients. Dual therapy combining nitazoxanide with azithromycin or doxycycline was more effective than monotherapy. Thus, the wide use of anti-infective drugs to prevent the spread of COVID-19 has significantly impacted the market. Moreover, post-pandemic, the market is growing at a stable pace owing to the decline in the demand for anti-infectives due to increased vaccination and decreasing COVID-19 cases globally.
The primary driving factor for the market's growth is the increasing burden of infectious diseases across developed and emerging markets, such as influenza, diarrhea, hepatitis, and urinary tract infections. For instance, according to the data published by the Centres for Disease Control and Prevention (CDC) in June 2022, an estimated 5% increase in the incidence of catheter-associated urinary tract infections (CAUTIs) in acute care hospitals was observed in the United States in 2021. The source also stated that the highest increase in incidence (9%) was observed in intensive care units (ICUs) of the hospitals. Thus, the growing burden of UTI increases demand for effective treatments such as anti-infectives, boosting market growth.
Moreover, several institutes have started specific initiatives or campaigns to increase awareness about infectious diseases among the public. For instance, in February 2022, the government of India implemented two phases of awareness campaigns for several infectious diseases such as HIV/AIDS, Tuberculosis. The campaign endeavors to generate awareness regarding the prevention of HIV/AIDS and TB, promotion of related services, and reduce stigma and discrimination related to HIV/AIDS and TB. Such a campaign will create awareness of infectious diseases, treatment, and management which is expected to increase the demand for anti-infective drugs, thereby boosting the market growth.
Furthermore, market players are adopted various strategies such as product launches, mergers, acquisitions, and partnerships to stay competitive in the anti-infective drug market, which is also projected to propel the market's growth over the forecast period. For instance, in January 2023, Alkem launched its novel anti-infective in India under the brand name Zidavi. The newly launched Zidavi, a novel combination of ceftazidime and avibactam, is used for multiple drug resistance infections. Similarly, in September 2022, Vernalis Research, a wholly owned subsidiary of HitGen Inc., and Unison Medicines Inc. reported a research collaboration in the United States in anti-infectives.
Hence, the growing burden of infectious diseases and rising awareness campaigns for contagious illnesses, coupled with the strategic activities by market players, are expected to boost the market growth over the forecast period. However, the shortage of resources in healthcare facilities, particularly in emerging markets, and the emergence of anti-infective drug resistance and the associated side effects restrict the growth of the studied market.
Anti Infective Drugs Market Trends
Antiviral Products are Expected Hold a Significant Share Over the Forecast Period
Anti-viral drugs are a class of medication used for treating viral infections. The broad-spectrum antiviral is effective against many viruses; most antivirals target specific viruses. Anti-viral drugs help reduce the risk of disease and shorten the time the affected person is sick. Some antiviral drugs are Acyclovir, Brivudin, Cidofovir, Famciclovir, and others. The rise in the incidence of viral diseases such as human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), hepatitis, and others, increasing awareness among the population about such diseases, and the rising number of research and development in the area are adding to the growth of the market.
The growing burden of several viral diseases such as HIV/AIDS, hepatitis, herpes infection, and others are creating a demand for effective treatments such as the antiviral drug, thereby boosting segment growth. For instance, as per the August 2022 update of the United States Department of Health & Human Services, an estimated 20.6 million people with HIV lived in eastern and southern Africa, 5 million in western and central Africa, and 6 million in Asia and Pacific in 2021. Further, according to the World Health Organization, an estimated 491 million people aged 15-49 worldwide were living with herpes simplex type 2 (HSV-2) infection in 2022. Thus, the massive burden of viral diseases is expected to boost segment growth.
Several market players have been focusing on producing and manufacturing anti-viral drugs, owing to their increasing necessity. For instance, in October 2021, Merck & Co., a pharmaceutical company, signed a voluntary licensing agreement with CDC. The agreement focused on facilitating affordable global access to molnupiravir, an investigational oral COVID-19 antiviral medicine for treating mild-to-moderate COVID-19 in adults at risk for progressing to severe COVID-19 and hospitalization. Similarly, in December 2022, Gilead Science received U.S. Food and Drug Administration approval for Sunlenca (lenacapavir), a new antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1). Such activities are expected to boost the antiviral segment growth over the forecast period.
Hence, market players' growing burden of viral diseases and strategic activities is expected to boost market growth over the forecast period.
North America is Expected to Hold a Major Market Share Over the Forecast Period
The North American region is expected to hold a significant share of anti-infective drugs market growth during the study period. Factors such as sophisticated healthcare infrastructure, high societal awareness, well-established distribution channels, and a good presence of e-commerce across the United States and Canada are expected to drive the market over the forecast period.
The high burden of various infectious diseases such as HIV/AIDS, hepatitis, herpes, tuberculosis, and pneumonia in the region is expected to create a demand for the treatment and management of these diseases, which is likely to boost market growth. For instance, according to the statistics published by the Centers for Diseases Control and Prevention in May 2023, in the United States, 1.2 million persons had HIV in 2021, and 36,136 individuals received an HIV diagnosis in 2021. Additionally, according to March 2023 updated statistics by Canada's Source for HIV and Hepatitis C Information, there were 1,722 HIV diagnoses in Canada in 2021. HIV infection is effectively treated and managed with anti-viral drugs such as abacavir, didanosine, etc. Hence, boosting the market growth over the forecast period.
Several key market players are also aiding the market's growth by launching several anti-infective drugs and establishing a solid regional footprint. For instance, in May 2022, the United States Food and Drug Administration approved VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK manufactured by Phathom Pharmaceuticals, Inc. VOQUEZNA DUAL PAK is indicated for the treatment of Helicobacter pylori infection. Similarly, in May 2023, Melinta Therapeutics, LLC and Xediton Pharmaceuticals Inc (Xediton) reported that they have entered into an exclusive commercialization and licensing agreement for BAXDELA (delafloxacin), KIMYRSA (oritavancin), ORBACTIV (oritavancin) and VABOMERE (meropenem and vaborbactam), four novel anti-infective products.
Hence, the growing burden of several infectious diseases and product launches by the market players in the region is expected to boost the market growth over the forecast period.
Anti Infective Drugs Industry Overview
The anti-infective drugs market is competitive and consists of many global and local players. The market participants are actively launching new products and obtaining approvals for them, which is anticipated further to intensify the competitive environment within the studied market. Some key players in the anti-infective drugs market are Novartis AG, Merck & Co., Inc, Sanofi SA, GSK, and Gilead Sciences, among others.
Anti Infective Drugs Market Leaders
-
Merck & Co., Inc
-
Gilead Sciences
-
GlaxoSmithKline PLC
-
Pfizer Inc
-
Novartis AG
*Disclaimer: Major Players sorted in no particular order
Anti Infective Drugs Market News
- In July 2023, AiCuris Anti-infective Cures AG reported that it had sharpened its strategic focus on the development of novel, therapeutic candidates for the prevention and treatment of moderate to severe and potentially life-threatening infectious diseases in immunocompromised patients.
- In July 2023, Lupin Limited reported that it had received tentative approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA), Dolutegravir Tablets for Oral Suspension, 5 mg to treat HIV/AIDS.
Anti Infective Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Prevalence of Targeted Diseases
- 4.2.2 Growing Initiatives for the Awareness of Infectious Diseases
- 4.2.3 Increasing Investments on R&D Activities of Anti-Infective Drugs
-
4.3 Market Restraints
- 4.3.1 Emergence of Anti-infective Drugs Resistance and Side Effects Associated with Anti-infective drugs
- 4.3.2 Shortage of Resources in Low- and Middle-income Countries (LMIC)
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Millions)
-
5.1 By Product Type
- 5.1.1 Antibiotics
- 5.1.2 Antivirals
- 5.1.3 Antifungals
- 5.1.4 Other Products
-
5.2 By Indication
- 5.2.1 HIV Infection
- 5.2.2 Pneumonia
- 5.2.3 Respiratory Virus Infection
- 5.2.4 Sepsis
- 5.2.5 Tuberculosis
- 5.2.6 Other Indications
-
5.3 By Distribution Channel
- 5.3.1 Hospital Pharmacy
- 5.3.2 Retail Pharmacy
- 5.3.3 Other Distribution Channels
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 Astellas Pharma Inc
- 6.1.3 Bayer AG
- 6.1.4 Bristol-Myers Squibb Company
- 6.1.5 Gilead Sciences, Inc
- 6.1.6 GlaxoSmithKline PLC
- 6.1.7 Merck & Co., Inc.
- 6.1.8 Novartis AG
- 6.1.9 Pfizer, Inc
- 6.1.10 Sanofi SA
- 6.1.11 Lupin Phamaceutical
- 6.1.12 Dr. Reddy's Laboratories Ltd
- 6.1.13 Glenmark Pharmaceuticals Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAnti Infective Drugs Industry Segmentation
As per the scope of the report, anti-infective drugs/agents are described as substances that prevent infectious agents or organisms from spreading. These are mostly communicable diseases spread by viruses, bacteria, fungi, and other organisms. The Anti-infective Drugs Market is Segmented by Product Type (Antibiotics, Antivirals, Antifungals, and Other Products), Indication (HIV Infection, Pneumonia, Respiratory Virus Infection, Sepsis, Tuberculosis, and Other Indications), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers the value in USD million for the above segments.
| By Product Type | Antibiotics | |
| Antivirals | ||
| Antifungals | ||
| Other Products | ||
| By Indication | HIV Infection | |
| Pneumonia | ||
| Respiratory Virus Infection | ||
| Sepsis | ||
| Tuberculosis | ||
| Other Indications | ||
| By Distribution Channel | Hospital Pharmacy | |
| Retail Pharmacy | ||
| Other Distribution Channels | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Anti Infective Drugs Market Research FAQs
What is the current Global Anti-infective Drugs Market size?
The Global Anti-infective Drugs Market is projected to register a CAGR of 3.5% during the forecast period (2024-2029)
Who are the key players in Global Anti-infective Drugs Market?
Merck & Co., Inc, Gilead Sciences, GlaxoSmithKline PLC, Pfizer Inc and Novartis AG are the major companies operating in the Global Anti-infective Drugs Market.
Which is the fastest growing region in Global Anti-infective Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Anti-infective Drugs Market?
In 2024, the North America accounts for the largest market share in Global Anti-infective Drugs Market.
What years does this Global Anti-infective Drugs Market cover?
The report covers the Global Anti-infective Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Anti-infective Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Pharmaceutical Quality Management Systems Industry Report
Statistics for the 2024 Pharmaceutical Quality Management Systems market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Pharmaceutical Quality Management Systems analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
